$PALI
PALISADE BIO, INC.

2022 Q1 Form 10-K Financial Statement

#000095017022004093 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.929M $3.227M $9.307M
YoY Change 70.29% -19.12% 7.35%
% of Gross Profit
Research & Development $959.0K $800.0K $2.430M
YoY Change 103.56% 95.12% 20.39%
% of Gross Profit
Depreciation & Amortization $1.000K $0.00 $2.000K
YoY Change -90.0% -100.0% -93.1%
% of Gross Profit
Operating Expenses $3.888M $4.027M $41.85M
YoY Change 98.98% -8.48% 350.19%
Operating Profit -$3.888M -$41.85M
YoY Change 98.98% 350.19%
Interest Expense $1.000K $5.089M $2.398M
YoY Change -99.94% -25545.0% 920.43%
% of Operating Profit
Other Income/Expense, Net -$317.0K $11.00K $15.24M
YoY Change -84.73% -1586.63%
Pretax Income -$4.205M $1.073M -$26.62M
YoY Change 83.62% -124.28% 63.59%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.205M $1.073M -$26.62M
YoY Change 4.34% -124.28% 157.86%
Net Earnings / Revenue
Basic Earnings Per Share -$12.96 -$2.86
Diluted Earnings Per Share -$259.2K $79.29K -$3.39
COMMON SHARES
Basic Shares Outstanding 18.23M 13.57M 9.310M
Diluted Shares Outstanding 324.5K 9.348M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.644M $10.50M $10.50M
YoY Change 1.28% -0.33% -0.33%
Cash & Equivalents $6.600M $10.50M $10.50M
Short-Term Investments
Other Short-Term Assets $1.528M $1.879M $1.729M
YoY Change -29.59% -16.12% -22.81%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $150.0K
Total Short-Term Assets $8.258M $12.37M $12.37M
YoY Change -5.68% 1281.03% -3.93%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $3.000K $112.0K
YoY Change -72.39% -40.0% 1020.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.00K $26.00K $26.00K
YoY Change 160.0% 160.0% 160.0%
Total Long-Term Assets $92.00K $138.0K $138.0K
YoY Change -42.26% -93.5% -18.82%
TOTAL ASSETS
Total Short-Term Assets $8.258M $12.37M $12.37M
Total Long-Term Assets $92.00K $138.0K $138.0K
Total Assets $8.350M $12.51M $12.51M
YoY Change -6.34% 314.44% -4.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.147M $1.323M $1.323M
YoY Change 120.58% -47.85% 103.54%
Accrued Expenses $580.0K $463.0K $1.086M
YoY Change 81.25% -83.1% -53.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $87.00K $87.00K
YoY Change -91.69%
Total Short-Term Liabilities $1.864M $2.496M $2.496M
YoY Change 83.66% -69.12% -22.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.694M $2.651M $2.651M
YoY Change 896.47% 3213.75% 3213.75%
Total Long-Term Liabilities $1.694M $0.00 $2.651M
YoY Change 896.47% -100.0% 3213.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.864M $2.496M $2.496M
Total Long-Term Liabilities $1.694M $0.00 $2.651M
Total Liabilities $3.558M $5.147M $5.147M
YoY Change 199.97% -49.13% 56.92%
SHAREHOLDERS EQUITY
Retained Earnings $98.80M $94.60M
YoY Change -141.08% -239.06%
Common Stock $183.0K $143.0K
YoY Change 534.84% 410.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.792M $7.365M $7.365M
YoY Change
Total Liabilities & Shareholders Equity $8.350M $12.51M $12.51M
YoY Change -6.34% 314.44% -4.12%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$4.205M $1.073M -$26.62M
YoY Change 4.34% -124.28% 157.86%
Depreciation, Depletion And Amortization $1.000K $0.00 $2.000K
YoY Change -90.0% -100.0% -93.1%
Cash From Operating Activities -$3.764M -$3.055M -$14.77M
YoY Change 201.12% 38.86% 209.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$54.00K
YoY Change
Cash From Investing Activities $0.00 $0.00 -$54.00K
YoY Change 800.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.209M
YoY Change 343.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -87.00K -554.0K 24.61M
YoY Change -107.55% 1202.06%
NET CHANGE
Cash From Operating Activities -3.764M -3.055M -14.77M
Cash From Investing Activities 0.000 0.000 -54.00K
Cash From Financing Activities -87.00K -554.0K 24.61M
Net Change In Cash -3.851M -3.609M 9.782M
YoY Change 3829.59% 64.05% -439.18%
FREE CASH FLOW
Cash From Operating Activities -$3.764M -$3.055M -$14.77M
Capital Expenditures $0.00
Free Cash Flow -$14.77M
YoY Change 209.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-33672
CY2021 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
5800 Armada Drive, Suite 210
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2021 dei City Area Code
CityAreaCode
858
CY2021 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2021 dei Trading Symbol
TradingSymbol
PALI
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q4 us-gaap Assets
Assets
12512000
CY2020Q4 us-gaap Assets
Assets
3019000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1323000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
275000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
39200000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18233479
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
713000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
59000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12374000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
896000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
0
CY2020Q4 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
1817000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2537000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2740000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1590000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2021Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
87000
CY2020Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
578000
CY2021Q4 pali Long Term Debt Related Party Current Maturities
LongTermDebtRelatedPartyCurrentMaturities
0
CY2020Q4 pali Long Term Debt Related Party Current Maturities
LongTermDebtRelatedPartyCurrentMaturities
469000
CY2021Q4 us-gaap Liabilities
Liabilities
5147000
CY2020Q4 us-gaap Liabilities
Liabilities
10118000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6797500
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14239177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14239177
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2496000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8082000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2651000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1830000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2774502
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2774502
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101862000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51396000
CY2021Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-94642000
CY2020Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-68026000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12512000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3019000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2430000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3099000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9307000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6198000
CY2021 us-gaap Operating Expenses
OperatingExpenses
41854000
CY2020 us-gaap Operating Expenses
OperatingExpenses
9297000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41854000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-9297000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2020 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
841000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23033000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38000
CY2021 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
CY2020 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021 us-gaap Interest Expense
InterestExpense
2398000
CY2020 us-gaap Interest Expense
InterestExpense
235000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2021 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2020 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
3247000
CY2020 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15238000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1025000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10322000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.72
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.72
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9309774
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774370
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9347944
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774370
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26616000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10322000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31735000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10322000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-8332000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10322000
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
9000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
29000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2014000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1184000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
28728000
CY2021 pali Stock Acquired During Period Value
StockAcquiredDuringPeriodValue
2000
CY2021 pali Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger
AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger
-51000
CY2021 pali Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants
AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants
26000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1891000
CY2021 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1689000
CY2021 pali Conversion Of Share Liability To Common Stock
ConversionOfShareLiabilityToCommonStock
33000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10322000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
CY2021 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
3247000
CY2020 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23033000
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
38000
CY2021 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
91000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
30117000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
-135000
CY2020 pali Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree
0
CY2021 pali Noncash Lease Expense
NoncashLeaseExpense
166000
CY2020 pali Noncash Lease Expense
NoncashLeaseExpense
143000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Accretion Expense
AccretionExpense
2339000
CY2020 us-gaap Accretion Expense
AccretionExpense
202000
CY2021 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
1881000
CY2020 pali Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
0
CY2021 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2020 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
841000
CY2020 pali Gain Loss From Change In Fair Value Of Share Liability
GainLossFromChangeInFairValueOfShareLiability
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1891000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2014000
CY2021 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
192000
CY2020 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-84000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
59000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1157000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-89000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2395000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1006000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1120000
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1494000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-168000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-141000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14773000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4768000
CY2021 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3279000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2021 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
3333000
CY2020 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2021 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1433000
CY2020 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
27000
CY2021 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
CY2021 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
0
CY2020 pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
41000
CY2020 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
379000
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
450000
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
19900000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5209000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1175000
CY2021 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
99000
CY2020 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
67000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
151000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
87000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24609000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1890000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9782000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2884000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3623000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
713000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
64000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
55000
CY2021 pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
135000
CY2020 pali Noncash Transaction Costs Shared With Acquiree
NoncashTransactionCostsSharedWithAcquiree
0
CY2021 pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
1184000
CY2020 pali Acquisition Costs Related To Stock Issuance
AcquisitionCostsRelatedToStockIssuance
0
CY2021 pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
28728000
CY2020 pali Issuance Of Common Stock To Former Shareholders Of Acquiree
IssuanceOfCommonStockToFormerShareholdersOfAcquiree
0
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
9503000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2021 pali Assets Assumed1
AssetsAssumed1
2000
CY2020 pali Assets Assumed1
AssetsAssumed1
0
CY2021 pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
41000
CY2020 pali Acquisition Related Vesting Of Rsus Assumed In Merger
AcquisitionRelatedVestingOfRsusAssumedInMerger
0
CY2021 pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
51000
CY2020 pali Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger
AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger
0
CY2021 pali Debt Discount For Issuance Of Warrants
DebtDiscountForIssuanceOfWarrants
0
CY2020 pali Debt Discount For Issuance Of Warrants
DebtDiscountForIssuanceOfWarrants
29000
CY2021 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1689000
CY2020 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
CY2021 pali Deferred Transaction Costs In Accounts Payable And Accrued Liabilities
DeferredTransactionCostsInAccountsPayableAndAccruedLiabilities
0
CY2020 pali Deferred Transaction Costs In Accounts Payable And Accrued Liabilities
DeferredTransactionCostsInAccountsPayableAndAccruedLiabilities
1817000
CY2021 pali Issuance Of Common Stock For Settlement Of Trade Payable
IssuanceOfCommonStockForSettlementOfTradePayable
0
CY2020 pali Issuance Of Common Stock For Settlement Of Trade Payable
IssuanceOfCommonStockForSettlementOfTradePayable
9000
CY2021 pali Debt Issuance Costs Included In Accounts Payable
DebtIssuanceCostsIncludedInAccountsPayable
0
CY2020 pali Debt Issuance Costs Included In Accounts Payable
DebtIssuanceCostsIncludedInAccountsPayable
61000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
94600000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10500000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to clinical trial accruals and the valuation of derivative liabilities and stock-based compensation instruments. Although these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2020Q4 pali Deferred Merger Transaction Costs
DeferredMergerTransactionCosts
1800000
CY2021 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
4700000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
CY2020 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31735000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10322000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26616000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10322000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9309774
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2774370
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.86
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.72
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-26616000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10322000
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
-5119000
CY2021 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
9309774
CY2020 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
2774370
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
38170
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9347944
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2774370
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.39
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.72
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9145075
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1339901
CY2021Q2 pali Number Of Directors
NumberOfDirectors
8
CY2021Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
195000
CY2020Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
1018000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2020Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
875000
CY2021Q4 pali Accrued Director Stipends
AccruedDirectorStipends
110000
CY2020Q4 pali Accrued Director Stipends
AccruedDirectorStipends
759000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2740000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2020Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
41000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1408000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
31000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
150000
CY2020Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
0
CY2021Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
215000
CY2020Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
35000
CY2021Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
78000
CY2020Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
0
CY2021Q4 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
26000
CY2020Q4 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
16000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
124000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
87000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2719000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1578000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
87000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
1141000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
87000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1047000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
94000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 pali Number Of Votes Per Share Of Common Stock
NumberOfVotesPerShareOfCommonStock
1
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7181741
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
195712
CY2020Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
195712
CY2020 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
21.20
CY2020 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P6Y7M6D
CY2021 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
7572191
CY2021 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
3.86
CY2021 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P4Y7M17D
CY2021 pali Class Of Warrant Or Right Assumed During Period
ClassOfWarrantOrRightAssumedDuringPeriod
749792
CY2021 pali Class Of Warrant Or Right Assumed During Period Weighted Average Exercise Price
ClassOfWarrantOrRightAssumedDuringPeriodWeightedAverageExercisePrice
21.07
CY2021 pali Class Of Warrant Or Right Assumed During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightAssumedDuringPeriodWeightedAverageRemainingContractualLife
P2Y6M29D
CY2021 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1309266
CY2021 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
3.88
CY2021 pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P4Y10M9D
CY2021 pali Class Of Warrant Or Right Settled During Period
ClassOfWarrantOrRightSettledDuringPeriod
20313
CY2021 pali Class Of Warrant Or Right Settled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightSettledDuringPeriodWeightedAverageExercisePrice
57.46
CY2021 pali Class Of Warrant Or Right Settled During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightSettledDuringPeriodWeightedAverageRemainingContractualLife
P2Y5M4D
CY2021 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
6375
CY2021 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
18.37
CY2021 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageRemainingContractualLife
P2Y8M26D
CY2021Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
7181741
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.96
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y5M12D
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.08
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
26.85
CY2021 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y7M17D
CY2020 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P8Y2M4D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7432
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.800
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
826769
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.72
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1541000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1219954
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M26D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
2100000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.08
CY2021 pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y10M9D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89868
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.10
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1956855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
779445
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.69
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M9D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.68
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
20.23
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
1200000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
400000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1891000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2014000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1900000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y29D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2020 pali Milestone Payments
MilestonePayments
0
CY2021 pali Milestone Payments
MilestonePayments
0
CY2021 pali License Issue Fee
LicenseIssueFee
10000
CY2021 us-gaap Royalty Expense
RoyaltyExpense
1900000
CY2021 us-gaap Lease Cost
LeaseCost
197000
CY2020 us-gaap Lease Cost
LeaseCost
194000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2021Q4 pali Operating Leases Future Minimum Payments
OperatingLeasesFutureMinimumPayments
117000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5000
CY2020Q2 pali Rent Deferral Agreement Related To The Covid19 Pandemic Proration Of Deferred Balance Period
RentDeferralAgreementRelatedToTheCOVID19PandemicProrationOfDeferredBalancePeriod
P6M
CY2020Q4 pali Rent Deferral Agreement Related To The Covid19 Pandemic Deferred Balance
RentDeferralAgreementRelatedToTheCovid19PandemicDeferredBalance
87000
CY2020Q4 pali Accrual For Suspended Salary Benefits And Bonuses To Be Paid Upon Closing Of Merger
AccrualForSuspendedSalaryBenefitsAndBonusesToBePaidUponClosingOfMerger
1100000
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
110000
CY2020Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
759000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1891000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
186000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
187000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5589000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2168000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1309000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
0
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
1000
CY2021 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-3609000
CY2020 pali Income Tax Reconciliation Nondeductible Expense Warrants
IncomeTaxReconciliationNondeductibleExpenseWarrants
-8000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
106000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
97000
CY2021 pali Income Tax Reconciliation Non Deductible In Process Research And Development Expense
IncomeTaxReconciliationNonDeductibleInProcessResearchAndDevelopmentExpense
5828000
CY2020 pali Income Tax Reconciliation Non Deductible In Process Research And Development Expense
IncomeTaxReconciliationNonDeductibleInProcessResearchAndDevelopmentExpense
0
CY2021 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
479000
CY2020 us-gaap Income Tax Reconciliation Minority Interest Income Expense
IncomeTaxReconciliationMinorityInterestIncomeExpense
0
CY2021 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
327000
CY2020 pali Income Tax Reconciliation Other Non Deductible Expenses
IncomeTaxReconciliationOtherNonDeductibleExpenses
0
CY2021 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
330000
CY2020 pali Income Tax Reconciliation Nondeductible Expense Expiration Of Tax Attributes
IncomeTaxReconciliationNondeductibleExpenseExpirationOfTaxAttributes
0
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-413000
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3664000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
59000
CY2020Q4 pali Deferred Tax Assets Accrued Expenses
DeferredTaxAssetsAccruedExpenses
512000
CY2021Q4 pali Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
206000
CY2020Q4 pali Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
0
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
1000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
0
CY2021Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
29000
CY2020Q4 pali Deferred Tax Assets Lease Accounting
DeferredTaxAssetsLeaseAccounting
59000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20904000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8073000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1737000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1438000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22936000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10082000
CY2021Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
28000
CY2020Q4 pali Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
57000
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
86000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
7000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
114000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
64000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
22822000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
10018000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22822000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10018000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0
CY2020 pali Uncertain Income Tax Positions
UncertainIncomeTaxPositions
0

Files In Submission

Name View Source Status
0000950170-22-004093-index-headers.html Edgar Link pending
0000950170-22-004093-index.html Edgar Link pending
0000950170-22-004093.txt Edgar Link pending
0000950170-22-004093-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img111677673_0.jpg Edgar Link pending
img111677673_1.jpg Edgar Link pending
img59148923_0.jpg Edgar Link pending
img59148923_1.jpg Edgar Link pending
img59148923_10.jpg Edgar Link pending
img59148923_11.jpg Edgar Link pending
img59148923_12.jpg Edgar Link pending
img59148923_13.jpg Edgar Link pending
img59148923_14.jpg Edgar Link pending
img59148923_15.jpg Edgar Link pending
img59148923_16.jpg Edgar Link pending
img59148923_17.jpg Edgar Link pending
img59148923_18.jpg Edgar Link pending
img59148923_19.jpg Edgar Link pending
img59148923_2.jpg Edgar Link pending
img59148923_20.jpg Edgar Link pending
img59148923_21.jpg Edgar Link pending
img59148923_22.jpg Edgar Link pending
img59148923_3.jpg Edgar Link pending
img59148923_4.jpg Edgar Link pending
img59148923_5.jpg Edgar Link pending
img59148923_6.jpg Edgar Link pending
img59148923_7.jpg Edgar Link pending
img59148923_8.jpg Edgar Link pending
img59148923_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20211231.htm Edgar Link pending
pali-20211231.xsd Edgar Link pending
pali-20211231_cal.xml Edgar Link unprocessable
pali-20211231_def.xml Edgar Link unprocessable
pali-20211231_htm.xml Edgar Link completed
pali-20211231_lab.xml Edgar Link unprocessable
pali-20211231_pre.xml Edgar Link unprocessable
pali-ex10_23.htm Edgar Link pending
pali-ex10_27.htm Edgar Link pending
pali-ex10_5.htm Edgar Link pending
pali-ex21_1.htm Edgar Link pending
pali-ex23_1.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
pali-ex4_2.htm Edgar Link pending
pali-ex4_3.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending